All In Biotech

Drug Trial Radar · NCT03841448

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

Last checked: Nov 20, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

31

Actual

Start

Sep 30, 2019

Primary completion

Mar 17, 2022

Study completion Jun 27, 2023

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.

Conditions

  • IgA Nephropathy (IgAN)
  • Berger Disease
  • Glomerulonephritis, IgA

Interventions

  • PlaceboDrug

    Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.

  • CemdisiranDrug

    Cemdisiran was administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in UPCR as Measured in 24-hour Urine at Week 32Time frame: Baseline to Week 32

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Vancouver, British Columbia, Canada

  • Clinical Trial Site

    Brampton, Ontario, Canada

  • Clinical Trial Site

    Toronto, Ontario, Canada

  • Clinical Trial Site

    Grenoble, France

  • Clinical Trial Site

    La Tronche, France

  • Clinical Trial Site

    Mulhouse, France

  • Clinical Trial Site

    Kuala Lumpur, Malaysia

  • Clinical Trial Site

    Kuantan, Malaysia

  • Clinical Trial Site

    Serdang, Malaysia

  • Clinical Trial Site

    Quezon City, Philippines

  • Clinical Trial Site

    Singapore, Singapore

  • Clinical Trial Site

    Córdoba, Spain

  • Clinical Trial Site

    Girona, Spain

  • Clinical Trial Site

    Huddinge, Sweden

  • Clinical Trial Site

    Uppsala, Sweden

  • Clinical Trial Site

    Taichung, Taiwan

  • Clinical Trial Site

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.